ArticlePharmaceutics2021
Folate-Equipped Cationic Liposomes Deliver Anti-MDR1-siRNA to the Tumor and Increase the Efficiency of Chemotherapy.
Article in Pharmaceutics, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed, 18 citations in OpenAlex.
- Loop-Structured PEG-Lipoconjugate Enhances siRNA Delivery Mediated by Liner-PEG Containing Liposomes.Molecules (Basel, Switzerland) · 2025Article
- Dox-HCl and miR-145 co-delivery through CD44-targeted PEGylated liposomes inhibit Breast CancerNanomedicine (London, England) · 2025Article
- Genosomes: An Introspection into Transfection, Future Perspectives and Applications.Advanced pharmaceutical bulletin · 2025Review
- Effect of structure and composition of cationic liposomes on the delivery of siRNAFrontiers in pharmacology · 2025Article
- Nanomedicine in Management of Cerebral Infarction and Brain Cancer: Role of Inflammation.Current medicinal chemistry · 2025Review
- Liposome-Based Drug Delivery Systems in Cancer Research: An Analysis of Global Landscape Efforts and Achievements.Pharmaceutics · 2024Article
- Recent advanced lipid-based nanomedicines for overcoming cancer resistance.Cancer drug resistance (Alhambra, Calif.) · 2024Review
- A Novel 3-ACS omega · 2023Article
- Influence of the Composition of Cationic Liposomes on the Performance of Cargo Immunostimulatory RNA.Pharmaceutics · 2023Article
- Design of Folate-Containing Liposomal Nucleic Acid Delivery Systems for Antitumor Therapy.Pharmaceutics · 2023Review
- The Role of Cryoprotective Agents in Liposome Stabilization and Preservation.International journal of molecular sciences · 2022Review
- Article
- Targeted Liposomes: A Nonviral Gene Delivery System for Cancer Therapy.Pharmaceutics · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors at 3 institutions in 1 country.
Funding
Abstract
In this study, we examined the in vivo toxicity of the liposomes F consisting of 1,26-bis(cholest-5-en-3-yloxycarbonylamino)-7,11,16,20-tetraazahexacosan tetrahydrochloride, lipid-helper 1,2-dioleoyl-sn-glycero-3-phosphoethanolamine and folate lipoconjugate (
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.